Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” video here TAMPA, Fla. and LONDON, May
Why Akari Therapeutics Stock Is Falling On Tuesday?
07:41am, Tuesday, 26'th May 2026
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
Akari Therapeutics Stock Jumps On Promising Preclinical Data
11:17am, Friday, 22'nd May 2026
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated pa
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models Data sup
Akari Therapeutics Announces $5.5 Million Private Placement Offering
08:30am, Thursday, 21'st May 2026
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing
Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase
09:05am, Monday, 18'th May 2026
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC A
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari's global intellectual property acr
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Increases By 151.7%
03:12am, Sunday, 26'th Apr 2026
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 14,622 shares, a growth of 151.7% from
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
09:00am, Tuesday, 21'st Apr 2026
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor r
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
08:50am, Thursday, 09'th Apr 2026
CEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implications for platform validation and development acceleration
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
08:05am, Wednesday, 18'th Mar 2026
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice mo
Akari Therapeutics Announces ADS Ratio Change
04:30pm, Tuesday, 17'th Mar 2026
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice mo
